NYSE:MTD - New York Stock Exchange, Inc. - US5926881054 - Common Stock - Currency: USD
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.
Get insights into the S&P500 index performance on Tuesday. Explore the top gainers and losers within the S&P500 index in today's session.
MongoDB and Asana downgraded: Wall Street's top analyst calls
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
According to a new Pew Research Center poll, roughly two-thirds (63%) of Americans support the idea of the government increasing taxes on large corporations and higher-income households. Read...
We have published an article titled Billionaire Richard Chilton’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Mettler-Toledo International Inc. (NYSE:MTD) stands against Richard Chilton’s other stock picks. Richard Chilton is a veteran investor and the founder of Chilton Investment Company, a long-standing and respected […]
WK Kellogg (KLG) on Tuesday lowered its full-year guidance to take into account the potential impact
Mettler-Toledo International's Q1 results reflect growth in the Laboratory business, a decline in Industrial, and continued weakness in the Food Retail segment.
Mettler-Toledo (MTD) delivered earnings and revenue surprises of 3.67% and 1%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: INGN
Glaukos (GKOS) delivered earnings and revenue surprises of 33.33% and 3.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: GKOS
Beyond analysts' top -and-bottom-line estimates for Mettler-Toledo (MTD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: GKOS
BofA analyst Michael Ryskin lowered the firm’s price target on Mettler-Toledo (MTD) to $1,250 from $1,500 and keeps a Neutral rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and Contract Research Organizations is “particularly negative” heading into earnings given that these companies “sit at the intersection of a number of policy changes from the Trump Administration,” including headwinds from NIH budget cuts and global tariffs, as well as broader macro concerns, especial